Malign Mezotelyoma ile Reaktif Mezotelyal Hiperplazi ayrımında, effüzyon materyallerinde GLUT-1, CD147 ve ProExC’nin tanısal değeri

Yıl 2021, , 165 - 171, 07.07.2021

Tolga Bağlan , Nural Onaral Erdoğan

https://doi.org/10.17517/ksutfd.866929

Öz

Amaç: Effüzyon materyallerinde malign mezotelyoma ile reaktif mezotelyal hiperplazisi ayırıcı tanısı önemli bir sorundur. Bu sorunun çözümü için immünhistokimyasal antikorlar yaygın olarak kullanılmaktadır. Bu çalışmanın amacı, MM'yi RMH'den ayırt etmede GLUT-1, CD147 ve ProExC’nin tanısal değerini belirlemektir.
Gereç ve yöntemler: İmmünhistokimyasal çalışma, klinik ve histopatolojik korelasyonu olan 26 MM olgusu ile 26 RMH olgusuna ait hücre bloğu kesitlerinden yapıldı. Antikorlar; boyanma yüzdesi ve boyanma şiddetine göre semikantitatif olarak değerlendirildi. Herbir antikorun tek başına ve kombine tanısal performansları hesaplandı.
Bulgular: GLUT-1 ile 26 MM olgusunun 25’inde (%96.1), 26 RMH olgusunun ise 6’sında (%23) immünhistokimyasal ekspresyon izlendi. MM ve RMH olguları arasında GLUT-1 ile boyama yüzdesi ve yoğunluğu açısından istatistiksel olarak anlamlı fark vardı (p <0,001). MM ve RMH olgularının tümünde CD147 ile pozitiflik saptandı. CD147 ile MM ile RMH olguları arasında istatistiksel olarak anlamlı bir fark yoktu. ProExC’nin ortalama boyanma yüzdesi, MM olgularında %14, RMH olgularında ise %3,5 bulundu (p <0,001). MM’yi RMH’den ayırt etmede ProExC’nin en iyi kesim değeri %7 olarak hesaplandı.
Sonuç olarak GLUT-1, MM'nin RMH'den ayırıcı tanısını sağlayan duyarlı ve özgül bir immünohistokimyasal belirteçtir. ProExC, MM'yi RMH'den ayırmada faydalı olabilir. CD147 ise MM ile RMH'nin ayırıcı tanısında yararlı değildir.

Anahtar Kelimeler

GLUT-1, CD147, ProExC, Mezotelyoma, Effüzyon, İmmünhistokimya

Destekleyen Kurum

Ankara Üniversitesi Araştırma Fonu

Proje Numarası

13L3330007

Diagnostic value of GLUT-1, CD147, ProExC in the differantial diagnosis between malign mesothelioma and reactive mesothelial hyperplasia in effusion materials

Öz

Objective: The differential diagnosis of malignant mesothelioma (MM) and reactive mesothelial hyperplasia (RMH) is an important problem in effusion materials. Immunohistochemical antibodies are widely used to solve this problem. The purpose of this study is to determine the diagnostic value of GLUT-1, CD147 and ProExC in distinguishing MM from RMH.
Material and methods: Immunohistochemical studies were performed on cell block sections from 26 cases of clinic and histopathologic confirmed MM and 26 RMH. The antibodies were evaluated semi-quantitatively based on the percentage and intensity of staining. The diagnostic performance of each antibody alone and combined was calculated.
Results: Immunohistochemical GLUT-1 expression was seen in 25 of 26 (%96.1) MM and in 6 of 26 (%23) RMH. There was statistically significant difference between MM and RMH cases in terms of the percentage and intensity of staining with GLUT-1 (p <0.001). CD 147 was found positive in %100 of MM cases and RMH cases. There was not statistically significant difference between MM and RMH cases with CD147. The mean staining percentage of ProExC was found %14 in MM cases and %3.5 in RMH cases (p <0.001). The best cut-off value of ProExC in distinguishing MM from RMH was calculated as 7%.
In conclusion GLUT-1 is a sensitive and specific immunohistochemical marker enabling differential diagnosis of MM from RMH. ProExC can be useful in differentiating MM from RMH. CD147 is not useful in the differential diagnosis of MM and RMH.

Anahtar Kelimeler

GLUT-1, CD147, ProExC, Mesothelioma, Effusion, Immunohistochemistry

Proje Numarası

13L3330007

Kaynakça

• 1.Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960 Oct;17(4):260-271.
• 2. Dikensoy O. Mesothelioma due to environmental exposure to erionite in Turkey. Curr Opin Pulm Med. 2008 Jul;14(4):322-325.
• 3. Lepus CM, Vivero M. Updates in Effusion Cytology. Surg Pathol Clin. 2018 Sep;11(3):523-544.
• 4-Lee AF, Gown AM, Churg A. IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations. Am J Surg Pathol. 2013 Mar;37(3):421-426.
• 5-Chang S, Oh MH, Ji SY, Han J, Kim TJ, Eom M et al. Practical utility of insulin-like growth factor II mRNA-binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations. Pathol Int. 2014 Dec;64(12):607-612.
• 6-Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology. 2003 Sep;43(3):231-238.
• 7-Hasteh F, Lin GY, Weidner N, Michael CW. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol. 2010 Apr 25;118(2):90-96.
• 8- Xin X, Zeng X, Gu H, Li M, Tan H, Jin Z et al. CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis. Sci Rep. 2016 Sep 9;6:32804.
• 9. Guo M, Baruch AC, Silva EG, Jan YJ, Lin E, Sneige N et al. Efficacy of p16 and ProExC immunostaining in the detection of high-grade cervical intraepithelial neoplasia and cervical carcinoma. Am J Clin Pathol. 2011 Feb;135(2):212-220.
• 10. Kinoshita Y, Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T et al. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma. Cancer Cytopathol. 2018 Jan;126(1):54-63.
• 11. Cozzi I, Oprescu FA, Rullo E, Ascoli V. Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions. Diagn Cytopathol. 2018 Jan;46(1):9-14.
• 12. Walts AE, Hiroshima K, McGregor SM, Wu D, Husain AN, Marchevsky AM. BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions. Diagn Cytopathol. 2016 Jul;44(7):599-606.
• 13. Chevrier M, Monaco SE, Jerome JA, Galateau-Salle F, Churg A, Dacic S. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology. Cancer Cytopathol. 2020 Dec;128(12):939-947.
• 14. Kato Y, Tsuta K, Seki K, Maeshima AM, Watanabe S, Suzuki K et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007 Feb;20(2):215-220. 15. Shen J, Pinkus GS, Deshpande V, Cibas ES. Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol. 2009 Apr;131(4):516-523.
• 16. Monaco SE, Shuai Y, Bansal M, Krasinskas AM, Dacic S. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol. 2011 Apr;135(4):619-627.
• 17. Ikeda K, Tate G, Suzuki T, Kitamura T, Mitsuya T. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations. Diagn Cytopathol. 2011 Jun;39(6):395-401.
• 18. Aratake Y, Marutsuka K, Kiyoyama K, Kuribayashi T, Miyamoto T, Yakushiji K et al. EMMPRIN (CD147) expression and differentiation of papillary thyroid carcinoma: implications for immunocytochemistry in FNA cytology. Cytopathology. 2010 Apr;21(2):103-110.
• 19. Bryson PC, Shores CG, Hart C, Thorne L, Patel MR, Richey L et al. Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas. Arch Otolaryngol Head Neck Surg. 2008 Jun;134(6):581-586.
• 20. Chen T, Zhu J. Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma. Med Oncol. 2010 Dec;27(4):1185-1191.
• 21. Pinheiro C, Longatto-Filho A, Soares TR, Pereira H, Bedrossian C, Michael C et al. CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma. Diagn Cytopathol. 2012 Jun;40(6):478-483. 22. Shroyer KR, Homer P, Heinz D, Singh M. Validation of a novel immunocytochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression in cervical cytology. Cancer. 2006 Oct 25;108(5):324-330.
• 23. Wang WC, Wu TT, Chandan VS, Lohse CM, Zhang L. Ki-67 and ProExC are useful immunohistochemical markers in esophageal squamous intraepithelial neoplasia. Hum Pathol. 2011 Oct;42(10):1430-1437.
• 24. Moatamed NA, Rao JY, Alexanian S, Cobarrubias M, Levin M, Lu D et al. ProEx C as an adjunct marker to improve cytological detection of urothelial carcinoma in urinary specimens. Cancer Cytopathol. 2013 Jun;121(6):320-328.
• 25. Kimura F, Kawamura J, Watanabe J, Kamoshida S, Kawai K, Okayasu I et al. Significance of cell proliferation markers (Minichromosome maintenance protein 7, topoisomerase IIalpha and Ki-67) in cavital fluid cytology: can we differentiate reactive mesothelial cells from malignant cells? Diagn Cytopathol. 2010 Mar;38(3):161-167.
• 26. Kimura F, Okayasu I, Kakinuma H, Satoh Y, Kuwao S, Saegusa M et al. Differential diagnosis of reactive mesothelial cells and malignant mesothelioma cells using the cell proliferation markers minichromosome maintenance protein 7, geminin, topoisomerase II alpha and Ki-67. Acta Cytol. 2013;57(4):384-390.